October 1998
Volume 39, Issue 11
Free
Articles  |   October 1998
Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes.
Author Affiliations
  • B Steen
    Department of Ophthalmology, St. Erik's Eye Hospital, Karolinska Institute, Stockholm, Sweden.
  • S Sejersen
    Department of Ophthalmology, St. Erik's Eye Hospital, Karolinska Institute, Stockholm, Sweden.
  • L Berglin
    Department of Ophthalmology, St. Erik's Eye Hospital, Karolinska Institute, Stockholm, Sweden.
  • S Seregard
    Department of Ophthalmology, St. Erik's Eye Hospital, Karolinska Institute, Stockholm, Sweden.
  • A Kvanta
    Department of Ophthalmology, St. Erik's Eye Hospital, Karolinska Institute, Stockholm, Sweden.
Investigative Ophthalmology & Visual Science October 1998, Vol.39, 2194-2200. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B Steen, S Sejersen, L Berglin, S Seregard, A Kvanta; Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes.. Invest. Ophthalmol. Vis. Sci. 1998;39(11):2194-2200.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

PURPOSE: Matrix metalloproteinases (MMP) are a family of extracellular matrix degrading enzymes associated with the development of neovascularization. To investigate the possible role of these enzymes in choroidal neovascularization, the mRNA expression of MMPs and tissue inhibitors of metalloproteinases (TIMPs) were analyzed in subfoveal fibrovascular membranes from patients with age-related macular degeneration (AMD). METHODS: Surgically removed subfoveal fibrovascular membranes from five eyes were analyzed for the expression of MMP and TIMP mRNA. In situ hybridization anti-sense and sense riboprobes were generated using DNA complementary to human collagenase (MMP-1), 72 kDa gelatinase (MMP-2), stromelysin (MMP-3), 92-kDa gelatinase (MMP-9), TIMP-1, TIMP-2, and TIMP-3. Vascular endothelial cells were detected using immunostaining for von Willebrand factor. RESULTS: MMP-2 and MMP-9 mRNA were detected in all specimens. Most of the membranes also expressed TIMP-1 and TIMP-3 mRNA, and two of the membranes expressed TIMP-2 mRNA. MMP-2, TIMP-1, and TIMP-2 mRNA had a similar overall distribution that was relatively uniform within the vascularized membrane stroma. MMP-2 expression appeared to be localized mainly to the vascular endothelial cells, whereas TIMP-1 and TIMP-3 were detected in other cell types such as fibroblastlike cells. MMP-9 expression was distinctly expressed by cells at the margins of the membranes and often in proximity to a thickened Bruch's membrane-like layer under the retinal pigment epithelial cells. TIMP-3 mRNA was strongly expressed within the retinal pigment epithelial cell layer and also in the stroma of one membrane. None of the membranes showed detectable MMP-1 or MMP-3 expression. CONCLUSIONS: The results support a role for MMPs in the development of choroidal neovascularization in AMD. The localization of MMP-2 and MMP-9 to the areas of new vessel formation and to the enveloping Bruch's-like membrane, respectively, suggests that MMP-2 and MMP-9 may be cooperatively involved in the progressive growth of choroidal neovascular membranes in AMD.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×